Time：18th Dce., 2018, 9:00-11:00 am
Venue：Conference room 406 in Biotechnology Building
Lecturer：ZHANG Cheng, KTH Royal Institute of Technology
Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic disease nowadays that happens in about one in four adults worldwide. However, there is no drug that could specifically be used for treating this disease because of the complexity of human body. In order to understand the pathogenesis and treatment of this disease, we need to investigate NAFLD in a global, systematic, multi-omics way. Systems biology is such kind of tool that could help us to understand human diseases in a systematic, wholistic and muli-omic way. In our study, we discovered a potential mechanism of NAFLD and developed a novel drug that could be specifically used for NAFLD treatment using systems biology tools. In addition, this drug is currently undergoing phase II clinical study.
ZHANG Cheng, Senior Research Fellow, Systems Biology Research Group, KTH Royal Institute of Technology. He received a bachelor's degree from East China University of Science and Technology in 2011 and received a Ph.D. degree from East China University of Science and Technology in 2016. From 2016 to 2017, he worked as a postdoctoral fellow at the Institute of Life Sciences of the KTH Royal Institute of Technology in Sweden. From 2017 to now, he was a Senior Research Fellow in Systems Biology Research Group, KTH Royal Institute of Technology. He has published 26 papers in journals such as Science, Cell, Cell Metabolism, Cell Systems, Nucleic Acids Research, PNAS, and Molecular Systems Biology, and has been cited more than 700 times.
Contact: Prof. ZHOU Yongjin, Group 18T6